Increased concentrations of IL-18 and uric acid in sickle cell anemia: Contribution of hemolysis, endothelial activation and the inflammasome

Cytokine

Volumn 56, Issue 2, 2011, Pages 471-476

  Cerqueira, Bruno A V ^a,b   Boas, Wendell V ^a   Zanette, Angela D ^c   Reis, Mitermayer G ^a   Goncalves, Marilda S ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^c Fundação de Hematologia e Hemoterapia do Estado da Bahia HEMOBA Salvador   (Brazil)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Cytokine; Inflammation; Sickle cell anemia

Indexed keywords

ARGINASE; BILIRUBIN; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 18; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARGINASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMOLYSIS; HUMAN; INTERLEUKIN 17 BLOOD LEVEL; INTERLEUKIN 18 BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SICKLE CELL ANEMIA; SOLUBLE VASCULAR ADHESION MOLECULE 1 BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CELL ADHESION MOLECULES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HEMOLYSIS; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; MALE; URIC ACID;

EID: 80053328301     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.013     Document Type: Article

References (37)

1. Buchanan G.R., DeBaun M.R., Quinn C.T., Steinberg M.H. Sickle cell disease, Hematology. Am Soc Hematol Educ Program 2004, 35-47.
2. Hebbel R.P. Perspectives series: cell adhesion in vascular biology. adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997, 99:2561-2564.
3. Platt O.S. Sickle cell anemia as an inflammatory disease. J Clin Invest 2000, 106:337-338.
4. Dinarello C.A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999, 103:11-24.
5. Khanna A. Interleukin-18, a potential mediator of inflammation, oxidative stress, and allograft dysfunction. Transplantation 2011, 91:590-591.
6. Stuyt R.J., Kim S.H., Reznikov L.L., Fantuzzi G., Novick D., Rubinstein M., et al. Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine 2003, 21:65-73.
7. Khan D.A., Ansari W.M., Khan F.A. Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J Interferon Cytokine Res 2011.
8. Lin Y.T., Wang C.T., Gershwin M.E., Chiang B.L. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011.
9. Greene C.M., Meachery G., Taggart C.C., Rooney C.P., Coakley R., O'Neill S.J., et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000, 165:4718-4724.
10. Lauw F.N., Simpson A.J., Prins J.M., Smith M.D., Kurimoto M., van Deventer S.J., et al. Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J Infect Dis 1999, 180:1878-1885.
11. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820.
12. Ono S., Ueno C., Seki S., Matsumoto A., Mochizuki H. Interleukin-12 and -18 induce severe liver injury in mice recovered from peritonitis after sublethal endotoxin challenge. Surgery 2003, 134:92-100.
13. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
14. Chiang E.Y., Frenette P.S. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005, 19:771-784.
15. Mantovani A., Sozzani S., Vecchi A., Introna M., Allavena P. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 1997, 78:406-414.
16. Yazdi A.S., Ghoreschi K., Rocken M. Inflammasome activation in delayed-type hypersensitivity reactions. J Invest Dermatol 2007, 127:1853-1855.
17. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
18. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
19. Boraschi D., Dinarello C.A. IL-18 in autoimmunity: review. Eur Cytokine Netw 2006, 17:224-252.
20. Leung B.P., Culshaw S., Gracie J.A., Hunter D., Canetti C.A., Campbell C., et al. A role for IL-18 in neutrophil activation. J Immunol 2001, 167:2879-2886.
21. Taylor, JGT, Nolan, VG, Mendelsohn, L, Kato, GJ, Gladwin, MT, Steinberg, MH, Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain, PLoS One 3 (2008) e2095.
22. Johnson R.J., Rodriguez-Iturbe B., Kang D.H., Feig D.I., Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18:431-440.
23. Ishizaka N., Ishizaka Y., Toda E., Nagai R., Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005, 25:1038-1044.
24. Viazzi F., Parodi D., Leoncini G., Parodi A., Falqui V., Ratto E., et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005, 45:991-996.
25. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190.
26. Koenig W., Meisinger C. Uric acid, type 2 diabetes, and cardiovascular diseases: fueling the common soil hypothesis?. Clin Chem 2008, 54:231-233.
27. Vilas-Boas W., Cerqueira B.A., Zanette A.M., Reis M.G., Barral-Netto M., Goncalves M.S. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Hematol 2010, 89:877-882.
28. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., et al. Uric acid and inflammatory markers. Eur Heart J 2006, 27:1174-1181.
29. Pfeffer K.D., Huecksteadt T.P., Hoidal J.R. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation. J Immunol 1994, 153:1789-1797.
30. Terada L.S., Piermattei D., Shibao G.N., McManaman J.L., Wright R.M. Hypoxia regulates xanthine dehydrogenase activity at pre- and posttranslational levels. Arch Biochem Biophys 1997, 348:163-168.
31. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005, 67:1739-1742.
32. Patterson R.A., Horsley E.T., Leake D.S. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003, 44:512-521.
33. Seixas M.O., Rocha L.C., Carvalho M.B., Menezes J.F., Lyra I.M., Nascimento V.M., et al. Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease. Lipids Health Dis 2010, 9:91.
34. Zorca S., Freeman L., Hildesheim M., Allen D., Remaley A.T., Taylor J.G.T., Kato G.J. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. Br J Haematol 2010, 149:436-445.
35. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
36. Shores J., Peterson J., VanderJagt D., Glew R.H. Reduced cholesterol levels in African-American adults with sickle cell disease. J Natl Med Assoc 2003, 95:813-817.
37. el-Hazmi M.A., Jabbar F.A., Warsy A.S. Cholesterol and triglyceride level in patients with sickle cell anaemia. Scand J Clin Lab Invest 1987, 47:351-354.